Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Carcinoma, Renal Cell × Tablets × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 6 Solid Tumors 2 Skin Neoplasms 2 Neoplasm Metastasis 2 Multiple Myeloma 2 Melanoma 2 Lung Neoplasms 2 Leukemia, B-Cell 2 Head and Neck Neoplasms 2 Breast Neoplasms 2 Vomiting 1 Urinary Bladder Neoplasms 1 Tracheal Diseases 1 TP53 Y220C Mutation 1 Squamous Cell Carcinoma of Head and Neck 1 Small Cell Lung Carcinoma 1 Sarcoma, Synovial 1 Sarcoma, Alveolar Soft Part 1 Sarcoma 1 Salivary Gland Neoplasms 1 Renal Insufficiency 1 Recurrence 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Osteosarcoma 1 Neuroblastoma 1 Nausea 1 Myofibroma 1 Mesothelioma 1

Interventions

pembrolizumab 74 Nivolumab 56 Sunitinib 48 Sorafenib 33 Everolimus 31 pazopanib 26 cabozantinib 23 Axitinib 23 Ipilimumab 22 Bevacizumab 20 belzutifan 17 atezolizumab 16 lenvatinib 15 avelumab 10 Paclitaxel 10 temsirolimus 8 Docetaxel 8 Cyclophosphamide 8 Interleukin-2 7 Interferon alpha-2 7 spartalizumab 6 fludarabine 6 durvalumab 6 tivozanib 5 aldesleukin 5 Ramucirumab 5 Cetuximab 5 cemiplimab 4 Interferon-alpha 4 Cisplatin 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01865747 2021-04-27

METEOR

Exelixis

Phase 3 Completed

658 enrolled 15 charts

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡